EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

24-month real-world persistence and compliance of denosumab versus alendronate among postmenopausal women with osteoporosis in Australia, Taiwan, South Korea, Hong Kong, and Singapore

Tang Ching Lau, Dong-Gune Chang, Chung-Hwan Chen, Shuang Huang, Edith M C Lau, Sheung-Wai Law, Young-Kyun Lee, Cae Tolman, Laura Canals, See-Hwee Yeo, Peter R Ebeling

Journal of Bone and Mineral Metabolism · 2026-09 · 44 (5) · 610-627

DOI: 10.1007/s00774-026-01736-w ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Bone and Mineral Metabolism, online erschienen am 17.06.2026. Verfasst von Tang Ching Lau und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. Hauptthemen laut MEDLINE: Alendronate, Denosumab, Osteoporosis, Postmenopausal, Bone Density Conservation Agents. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Amgen Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

To compare 24-month persistence and compliance of denosumab with alendronate in postmenopausal women with osteoporosis across 5 Asia–Pacific territories. Materials and methods This prospective cohort study included women aged ≥ 50 years from Australia, Taiwan, South Korea, Hong Kong, and Singapore. Participants received either a bi-annual denosumab injection or weekly oral alendronate as osteoporosis treatment, based on physician judgment. Multivariable logistic regression assessed whether therapy (denosumab or alendronate) was significantly associated with treatment persistence and compliance over 24 months of follow-up. The models were adjusted for age, fracture history, baseline bone mineral density (BMD), prior osteoporosis therapy, and prior oral glucocorticoid treatment. Adjusted odds ratios (aORs) and 95% confidence intervals (CIs) were calculated.

Results

Among 687 enrolled patients, 549 completed their 24-month visit (295 in denosumab and 254 in alendronate group). Patients in the denosumab group were older and a higher proportion previously received osteoporosis treatment. Overall treatment persistence and compliance were 74.9% and 56.6%, respectively. Patients prescribed with denosumab exhibited higher persistence (86.1% vs. 61.8%; P < 0.001) and compliance (62.4% vs. 50.0%; P = 0.004), compared with those on alendronate. Regression results also demonstrated that patients receiving denosumab were more likely to be persistent (aOR = 3.91; 95% CI 2.52–6.08), and compliant (aOR = 1.61; 95% CI 1.12–2.31). BMD T-scores improved in both the treatment groups after 24 months with no significant association between treatment type and change in T-score. No significant difference was also observed in the occurrence of adverse events between the two treatment cohorts. Patients on alendronate reported gastrointestinal issues more frequently, whereas those on denosumab had a higher incidence of bone and joint injuries.

Conclusion

Postmenopausal women with osteoporosis were more likely to be persistent and compliant with a bi-annual denosumab injection, compared with weekly oral alendronate.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AlendronateDenosumabOsteoporosis, PostmenopausalBone Density Conservation AgentsHumansFemaleMiddle AgedAgedRepublic of KoreaHong KongSingaporeTaiwanAustraliaProspective StudiesBone Density

Stichwörter der Autor:innen

AlendronateDenosumabMedication complianceMedication persistenceOsteoporosis

Substanzen

AlendronateDenosumabBone Density Conservation Agents

Autor:innen und Institutionen

  • Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
  • Department of Orthopedic Surgery, Inje University Sanggye Paik Hospital, College of Medicine, Inje University, Seoul, South Korea.
  • Department of Orthopedics and Orthopedic Research Center, Kaohsiung Medical University Hospital, College of Medicine, Regenerative Medicine and Cell Therapy Research Center, Kaohsiung Medical University, Kaohsiung, Taiw…
  • Amgen Inc., Thousand Oaks, CA, USA.
  • Hong Kong Orthopaedic and Osteoporosis Center for Treatment and Research, Hong Kong, China.
  • Department of Orthopaedics and Traumatology, The Chinese University of Hong Kong, Sha Tin, Hong Kong SAR, China.

Förderung

  • Amgen Foundation

Zitieren

APA

Lau, T. C., Chang, D. G., Chen, C. H., Huang, S., Lau, E. M. C., Law, S. W., Lee, Y. K., Tolman, C., Canals, L., Yeo, S. H., & Ebeling, P. R. (2026). 24-month real-world persistence and compliance of denosumab versus alendronate among postmenopausal women with osteoporosis in Australia, Taiwan, South Korea, Hong Kong, and Singapore. Journal of Bone and Mineral Metabolism, 44(5), 610-627. https://doi.org/10.1007/s00774-026-01736-w

Vancouver

Lau TC, Chang DG, Chen CH, Huang S, Lau EMC, Law SW, et al. 24-month real-world persistence and compliance of denosumab versus alendronate among postmenopausal women with osteoporosis in Australia, Taiwan, South Korea, Hong Kong, and Singapore. Journal of Bone and Mineral Metabolism. 2026;44(5):610-627. doi:10.1007/s00774-026-01736-w

BibTeX
@article{Lau2026,
  author = {Lau, Tang Ching and Chang, Dong-Gune and Chen, Chung-Hwan and Huang, Shuang and Lau, Edith M C and Law, Sheung-Wai and Lee, Young-Kyun and Tolman, Cae and Canals, Laura and Yeo, See-Hwee and Ebeling, Peter R},
  title = {24-month real-world persistence and compliance of denosumab versus alendronate among postmenopausal women with osteoporosis in Australia, Taiwan, South Korea, Hong Kong, and Singapore},
  journal = {Journal of Bone and Mineral Metabolism},
  year = {2026},
  volume = {44},
  number = {5},
  pages = {610--627},
  doi = {10.1007/s00774-026-01736-w}
}
Kostenlos starten →